Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes (T2DM). Evidence from recent cardiovascular safety trials in T2DM is changing clinical and pharmacy practice in new ways that go beyond A1C lowering. This program will support pharmacists in understanding how the pharmaceutical approaches for these patients has changed in the April 2018 update to the Diabetes Canada guidelines, and the evolving role of pharmacists in vascular and renal protection.
Type 2 Diabetes: New Guidelines go Above and Beyond A1C Lowering – Canadian Council On Continuing Education In Pharmacy (CCCEP)
CAN-eng
$0
free
CCCEP
1.5 hrs
Endocrinology
1.5 Credits
Course Description
Course Details
Expiry Date: 2019-10-09
Professions: Pharmacy
Faculty
Jessie Haggai (BSc Pharm, CDE), Rob Roscoe (BSc Pharm, ACPR, CDE, CPT, CDE), Sean Wharton (MD, PharmD)
Accreditation
File No. 1066-2018-2546-I-P
Accredited for 1.5CEU(s)
Program Accreditation Expires on 10/10/2019
Learning Objective(s)
Upon completion of this program, participants will be able to:
- Differentiate new rapid and long acting basal analogues from older agents and their impact on hypoglycaemia and glucose variability;
- Know when and how to switch from one insulin to another;
- Assess the benefit of emerging fixed-ratio combinations of basal-insulin plus GLP-1R agonist.